Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Health-Care Leaders Question How Remedesivir Is Being Distributed -- Update

share with twitter share with LinkedIn share with facebook
05/07/2020 | 04:54pm EDT

By Stephanie Armour and Joseph Walker

Health-care leaders are expressing concern over how the Trump administration plans to distribute the promising coronavirus drug remdesivir, saying they are in the dark about the allocation criteria being used and are worried it isn't based on need.

Some hospital officials say they have been informed they can't get the drug since the federal government took over its allocation following the Food and Drug Administration's emergency use authorization on May 1.

"Patients are going to die if we can't get access," said Dr. Amy Compton-Phillips, chief clinical officer at Providence St. Joseph Health in Seattle. "We need transparency on who is getting remdesivir."

That lack of clarity surrounding the drug's allocation is prompting health-care professionals to question whether remdesivir is being distributed based on need or other considerations.

Providence Health was involved in national clinical trials to test remdesivir in patients with severe and moderate Covid-19, the disease caused by the new coronavirus. Officials there now say they can no longer get the drug for patients because they haven't been selected by the government to receive it.

Health and Human Services and the Federal Emergency Management Agency, which are handling allocation, didn't immediately return emails seeking comment.

"We have sick patients now," said Dr. Michael G Ison, at Northwestern University Feinberg School of Medicine in Chicago, adding that they can't get the drug. "It's a mess. The critical issue is that there has been a plan put in place and no clarity put in place."

Gilead Sciences Inc., which developed remdesivir, has pledged to donate 1.5 million doses -- or enough to treat up to about 190,000 patients -- that it expects to manufacture by the end of this month. Supply of the drug is limited, and some analysts predict shortages relative to demand this summer. Gilead says it aims to produce enough remdesivir to treat more than one million patients by the end of 2020.

After receiving emergency use authorization, the company said it isn't playing a role in deciding how to allocate the donated supply of the drug in the U.S.

"Gilead is not deciding which hospitals will receive remdesivir," a Gilead spokesman said in an email on Thursday. Because remdesivir has only been shown to be effective in severely sick patients, and is in short supply, "hospitals with intensive care units and other hospitals that the government deems most in need will receive priority in the distribution of remdesivir."

The University of California San Francisco's hospital system learned this week that it wasn't chosen to receive the drug after calling AmerisourceBergen Corp., says Peter Chin-Hong, an infectious-disease specialist and professor of medicine at the university. Dr. Chin-Hong says his hospital, UCSF Medical Center, typically has around 20 Covid-19 patients receiving inpatient treatment, including those referred from local hospitals.

Amerisource, a drug wholesaler, is the exclusive distributor of remdesivir, according to Gilead.

At the moment, UCSF doesn't have patients who it would like to treat with remdesivir but can't, but Dr. Chin-Hong worries that could change quickly. "It's just the uncertainty," says Dr. Chin-Hong. "We've been blessed to have it, but the well is going to run out soon and we don't know when it's going to rain again."

Dr. Chin-Hong and his colleagues have been surveying doctors at hospitals around the U.S. caring for Covid-19 patients on whether they've been selected to receive the drug and posting the results online.

So far about 25 hospitals asked have said they were selected, Dr. Chin-Hong says.

National Institute of Allergy and Infectious Diseases said that a preliminary analysis of its study showed that hospitalized Covid-19 patients taking remdesivir had a speedier recovery than patients taking a placebo -- though the reported benefit was moderate, with remdesivir patients recovering in 11 days, or four days faster than the placebo group.

In an emailed statement, an Amerisource spokesman said "decisions on which hospitals and the quantity of the product they will receive are being made by the government," and Amerisource is working to "move any product we receive from Gilead in keeping with the government's directives."

Amerisource is distributing remdesivir to hospitals across the U.S. "regardless of whether they are AmerisourceBergen customers," the spokesman said. Hospitals designated by the U.S. government to receive donated remdesivir will be contacted directly by Amerisource, according to a notice on the company's website.

"From what we can tell, it's not based on need," said Helen Boucher, division of geographic medicine and infectious diseases chief at Tufts Medical Center. She said information on the clinical trial also needs to be shared by the federal government to help guide medical decisions.

The plan for distributing remdesivir should be transparent and based on state and regional case data and hospitalization rates, according to a letter sent Thursday to Vice President Mike Pence from the Infectious Diseases Society of America and the HIV Medicine Association.

The groups, which represent over 12,000 infectious diseases and HIV physicians, scientists, and others, said allocation should be on a regional basis that's equitable within the region to states and within states to hospitals.

This will be imperative to ensure appropriate patient access and "reduce the significant health disparities and adverse outcomes already experienced by Black Americans, Latinx communities and other populations, " the letter says.

Write to Stephanie Armour at stephanie.armour@wsj.com and Joseph Walker at joseph.walker@wsj.com


Stocks mentioned in the article
ChangeLast1st jan.
ACCESS CO., LTD. -3.47% 917 End-of-day quote.-3.98%
AMERISOURCEBERGEN CORPORATION 0.64% 100.09 Delayed Quote.18.53%
AMP LIMITED -0.80% 1.87 End-of-day quote.-2.35%
AT HOME GROUP INC. 3.91% 6.64 Delayed Quote.16.18%
CHANGE INC. -1.33% 7400 End-of-day quote.154.47%
GILEAD SCIENCES, INC. 0.38% 76.35 Delayed Quote.17.05%
JUST GROUP PLC 0.10% 51.2 Delayed Quote.-35.25%
LINE CORPORATION 0.92% 5470 End-of-day quote.2.24%
THE NEW HOME COMPANY INC. 0.63% 3.2 Delayed Quote.-31.76%
WILL GROUP, INC. -4.08% 634 End-of-day quote.-49.36%
share with twitter share with LinkedIn share with facebook
Latest news on GILEAD SCIENCES, INC.
09:09aGILEAD SCIENCES : Demonstrates Commitment to Scientific Innovation in HIV with N..
07/01World takes stock of COVID-19 drug remdesivir after U.S. snaps up supplies
07/01S.Korea talks COVID-19 drug, U.S. buys most stocks
07/01GILEAD SCIENCES : South Korea to start talks on COVID-19 drug remdesivir purchas..
06/30Scottish firm to trial T cells as possible COVID-19 treatment
06/30GILEAD SCIENCES : An Open Letter from Daniel O'Day, chairman and CEO, Gilead Sci..
06/30WHAT'S NEWS : Business & Finance -- WSJ
06/29NEWS HIGHLIGHTS : Top Company News of the Day
06/29GILEAD SCIENCES : Covid-19 Drug Remdesivir to Cost $3,120 for Typical Patient --..
More news
Financials (USD)
Sales 2020 22 748 M - -
Net income 2020 4 113 M - -
Net cash 2020 1 769 M - -
P/E ratio 2020 23,9x
Yield 2020 3,54%
Capitalization 95 408 M 95 408 M -
EV / Sales 2019
EV / Sales 2020 4,12x
Nbr of Employees 11 800
Free-Float 99,4%
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 31
Average target price 80,52 $
Last Close Price 76,06 $
Spread / Highest target 27,5%
Spread / Average Target 5,86%
Spread / Lowest Target -23,7%
EPS Revisions
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
WUXI APPTEC CO., LTD.41.34%30 875
GENMAB A/S47.28%21 551
BEIGENE, LTD.14.13%14 713